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L E T T E R
Systemicmastocytosis with an associated hematological
neoplasms: One or two entities?
Mastocytosis refers to a group of disorders characterized by excessive
mast-cell accumulation in one or multiple tissues. The WHO classifi-
cation [1] splits mastocytosis from the myeloproliferative neoplasms
as a distinctive entity group. SM-AHN was introduced as abbreviation
name of the 2008 category of “systemic mastocytosis with associated
clonal hematological non-mast-cell lineage disease" (SH-AHNMD) and
recognized as a subgroup of systemic mastocytosis. Approximately 5%
of SM cases are associated with myeloid malignancies, according to
the WHO classification, the most commonly detected AHN is CMML
[1]. Here, we report a case with the diagnosis of SM-AHN combining
SM and CMML. We aim to show that SM-AHN with CMML may be
overestimated, and that monocytosis may be an integral component of
the SM.
A 62-year-old caucasian man was referred to our outpatient clinic
in July 2018 with suspicion of myeloid disease. The patient com-
plained about episodes of extreme fatigue, drenching night sweats,
fever, skin hematomas, and weight loss of about 8 kg within 6 months.
The initial blood examinations documented a hemoglobin level of
10.5 g/dL, platelet count of 98 × 109/L, and white blood cell count
of 13.5 × 109/L showing a differential count with 8.47 × 109/L neu-
trophils, 0.98 × 109/L lymphocytes, and 2.29 × 109/L monocytes (17%
of total leukocytes), no eosinophilia or basophilia. Serum tryptase level
was increased at 139 µg/L (normal < 13 µg/L) with a normal serum
lactate dehydrogenase of 313 U/L. A full-body computed-tomography
scan revealed homogenous splenomegaly with a bipolar diameter of
18.5 cm.
The morphological examination of the initial bone marrow (BM)
aspirate and trephine biopsy performed in July 2018, revealed
hypercellularity for his age with marked proliferation of dysplastic
granulopoiesis and megakaryopoiesis, reduced erythropoiesis and the
presence of dense mast cell aggregates with atypical spindle-shape.
The blast count was not increased. BM fibrosis was evident (MF-2). SM
was diagnosed (major criterion and four minor criteria) (Figure 1). The
diagnostic criteria of CMMLwere additionallymet (all five criteria) and
fittingly, the diagnosis of SM-AHN was assumed. Cytogenetic testing
revealed a normal male karyotype. The molecular analysis of the initial
BM sample revealed KITD816Vmutation with 90%VAF (variant allele
frequency) (Realtime PCR, cDNA). Next Generation Sequencing (NGS)
showed positivity for ASXL1with 50%VAF, SRSF2 with 37% VAF, TET2
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with 100% VAF as well as the known KIT D816V mutation with a VAF
of 46%. For KIT D816V, the differences observed between the results
obtained by quantitative PCR andNGSwere explained by the different
starting material, genomic DNA material for NGS and RNA for the
quantitative PCR. Quantification of a mutation on the basis of RNA
depends on the expression of themutated gene.
Disease evolution was characterized by accelerated progression of
hepato- and splenomegalywithin 4months (November2018)while the
monocytosis remained stable.We hypothesize that themonocytosis in
this case was rather an expression of the underlying mastocytosis and
not necessarily proof of evidence of an associated disease as stated in
the WHO’s diagnostic proposition. We aimed therefore to investigate
the molecular characteristics of the monocytes from peripheral blood
and compared it with themutations found in the BM.
Subsequently, in January 2019, in order to separate monocytes
from peripheral blood by flow cytometry sorting, we first enriched and
isolated peripheral bloodmononuclear cells (PBMC) from EDTA-blood
by density centrifugation. PBMC were subsequently stained for
15 min in phosphate-buffered saline (PBS) using anti-CD45 V500,
anti-CD14 APC-H7, and anti-CD64 APC. PBMC were then washed
and resuspended in PBS at a cell density of 107 cells/mL. Samples were
analyzed immediately after labeling using a BD FACSAria III instru-
ment. We used Fluorescence activated cell sorting (FACS) method,
monocytes were sorted based on FSCdim/SSCdim and expression of
CD45, CD14, and CD64. Monocyte post-sorting purity was 97%.
At the time of molecular investigations of peripheral blood, on the
isolatedmonocytes and saliva sample, the patient had not received any
type of treatment.
For the molecular analysis, only those mutations identified previ-
ously in the BM were investigated in the sorted monocytes (Table 1).
Themonocytes harbored the followingmutations:KITD816VwithVAF
of 47%, ASXL1 with a VAF of 52%, SRSF2 with a VAF of 53% and TET2
mutationwith aVAF of 100%.Moreover, the high allele burden of TET2
mutation suggested a germline mutation, so we additionally tested
the TET2 variant p(Asn275Ilefs*18) in a saliva sample using Sanger
Sequencing. This was positive with a VAF of 50% suggesting a somatic
mutation.
The patient developed a rapidly progressive splenomegaly
(26 cm), intrahepatic segmental portal vein thrombosis and extended
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F IGURE 1 Bonemarrow biopsy of the patient. Trephine Biopsy, hematoxylin and eosin (H&E) stain, overview (A) showing a hypercellular bone
marrow dominated bymultifocal paratrabecular mast cell aggregates (10% of cellularity) and trilinear maturation of haemopoiesis with
predominance of themyelod lineage. Detailed image of atypical paratrabecular mast cell aggregates (B). c-kit immunohistochemistry (C) marks
multiple, paratrabecular atypical mast cell aggregates. Increased numbers of macrophages are observed in a CD68 immunohistochemistry (D),
showing a slight increase inmonocytic cells
TABLE 1 Mutations in the different cell compartments
Mutation Method BM Full blood Monocytes Saliva
Date collected 21 July 2018 22 January 2019 22 January 2019 22 January 2019
VAF VAF VAF VAF
KIT D816V PCR 90% 43% 47% –
NGS 46% – – –
ddPCR – 43% 47% –
SRSF2 NGS 37% 47% 53% –
ASXL1 NGS 50% 48% 52% –
TET2 NGS 100% 90% 100% –
Sanger sequencing – – – 50%
For NGS, we used the Ion Torrent S5 platform (Thermo Fisher Scientific, Reinach, Switzerland) including IonChef, and the human genome assembly GRCh37
(hg19) for variant calling. The original bone marrow sample was sequenced using the Ampliseq Oncomine myeloid panel (40 genes/hotspots; Thermo Fisher
Scientific, Reinach, Switzerland). VAF, variant allele frequency. All molecular investigationswere done before the patient received the hypomethylating treat-
ment and also before he underwent an allogeneic hematopoietic stem cell transplantation.
four-quadrant ascites after three cycles of hypomethylated therapy.
On May 2019, the patient underwent an allogeneic hematopoietic
stem cell transplantation from his human leukocyte antigen genoiden-
tical brother. To date, the patient is alive, however without achieving
hematologic remission, and has extensive cutaneous graft-versus-host
disease.
The definition of the role of monocytosis in the diagnosis of myeloid
diseases has been topic of discussion for a long time. Monocytosis
may accompany many myeloid diseases; the latest WHO update con-
sidered this aspect particularly for the diagnosis of CMML, defining
that monocytosis not only has to be greater than 1.0 × 109/L, but
also has to exceed 10% of the total leukocytes count [1]. This new
cutoff should certainly contribute to a better differentiation of many
myeloid entities; however, it remains arbitrary and may not be valid
in all cases. The identification of BCR-ABL1, PDGFRA, PDGFRB FGFR1
PCM1-JAK2 mutations together with the criteria for the diagnosis of
specific diseases like chronic myeloid leukemia, primary myelofibro-
sis, polycythemia vera, and essential thrombocythemiawill rule out the
diagnosis of CMML. In all these diseases, monocytosis per se as a cri-
terion is therefore overruled. Mastocytosis is currently not included in
this consideration.
Some authors described that multilineage KIT involvement and
multi-mutated clones are characteristic of advanced SM, and men-
tioned that this is particularly true when associated with hematologic
neoplasms [2–4]. The presence of KIT D816V was first reported in
monocytic cell of BM [2] and a further publication also identified KIT
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D816Vmutation in variable myeloid subtypes of marrow cells of AHN
[3]. Among multilineage SM patients, the presence of the KIT D816V
mutation is typically detected in genomic DNA (gDNA) of CD34+
hematopoietic stem and precursor cells, eosinophils, monocytes, and
maturing neutrophils, and, to a less extent, also in T lymphocytes, in
addition to bone marrow mast cells [5]. Using highly sensitive PCR
technique, KIT D816V mutation can be found in peripheral blood of
adult SM patients [6]. A recent a paper revisited the issues related to
CMML diagnosis and prognostication in which SM with concomitant
CMML is considered as a separate entity within the special variants
of CMML (SM-CMML). This international consensus group highlighted
as a key diagnostic feature to discriminate the variant from classical
CMML, thepresenceofKITD816V inmost ofCMMLmonocytes 7].We
did not find previous data reporting on the molecular profile beyond
KIT D816V of isolated monocytes from peripheral blood of SM-AHN
patients.
Historically, monocytosis has proven to be a great confounder. The
advances in molecular diagnostics and the improvement of the diag-
nostic criteria for myeloid neoplasms in the past two decades have
contributed to delimiting some myeloid neoplasms even with notice-
able monocytosis from CMML [1,7–9]. In the case presented, the dis-
ease that drove the clinical picture was clearly the SM. Formally, the
persistentmonocytosis allowed the diagnosis of CMML. The confirma-
tion that the isolated monocyte harbored all mutations found in BM
inclusive KIT (Table 1) suggests that the monocytes might be rather
the expression of the SM and may perhaps not represent a second dis-
ease. Associating other diseases with systemic mastocytosis can be a
distracting factor to focus treatment properly [10]. We consider that a
most appropriate nomenclature for such cases needs to be defined.
AUTHOR CONTRIBUTIONS
LN and AR contributed to the writing of the manuscript and creation
of the table. NP contributes with molecular analysis. MF contributed
with the flow cytometry sorting. UB contributed with molecular anal-
ysis and diagnostic. YB contributed with the histological diagnosis and
creation of the figure. All authors reviewed and approved the final ver-
sion of this manuscript.
CONFLICT OF INTEREST
The authors have declared no conflict of interest.
Linet Njue1
Naomi Porret1
Michaela Fux2
Ulrike Bacher1
Yara Banz3
Alicia Rovó1
1Department of Hematology and Central Hematology Laboratory,
Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
2University Institute of Clinical Chemistry, Inselspital, Bern University
Hospital, University of Bern, Bern, Switzerland
3Institute of Pathology, University of Bern, Bern, Switzerland
Correspondence
Alicia RovóMD, Senior Attending/Deputy Physician-in-Chief and,
Head of the Clinical Unit Hematology, Department of Hematology, and
Central Hematology Laboratory, Inselspital, Bern University Hospital,
University of Bern, 3010 Bern, Switzerland.
Email: alicia.rovo@insel.ch
ORCID
Alicia Rovó https://orcid.org/0000-0002-7757-4753
REFERENCES
1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World
Health Organization classification of myeloid neoplasms and acute
leukemia. Blood. 2016;127:2391–2405.
2. Sotlar K, Marafioti T, Griesser H, et al. Detection of c-kit mutation
Asp 816 to Val in microdissected bone marrow infiltrates in a case
of systemic mastocytosis associated with chronic myelomonocytic
leukaemia.Mol Pathol. 2000;53:188–193.
3. Sotlar K, Colak S, Bache A, et al. Variable presence of KITD816V
in clonal haematological non-mast cell lineage diseases associated
with systemic mastocytosis (SM-AHNMD). J Pathol. 2010;220:586–
595.
4. Reiter A, George TI, Gotlib JR. New developments in diagnosis, prog-
nostication, and treatment of advanced systemic mastocytosis. Blood.
2020;135:1365-1376.
5. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT muta-
tion in mast cells and other bone marrow hematopoietic cell lineages
in systemic mast cell disorders: a prospective study of the Spanish
Network on Mastocytosis (REMA) in a series of 113 patients. Blood.
2006;108:2366–2372.
6. Jara-Acevedo M, Teodosio C, Sanchez-Munoz L, et al. Detection of the
KIT D816V mutation in peripheral blood of systemic mastocytosis:
diagnostic implications.Mod Pathol. 2015;28:1138–1149.
7. Valent P, Orazi A, Savona MR, et al. Proposed diagnostic criteria for
classical chronic myelomonocytic leukemia (CMML), CMML variants
and pre-CMML conditions.Haematologica. 2019;104:1935–1949.
8. Craig JW, Hasserjian RP, Kim AS, et al. Detection of the KIT(D816V)
mutation in myelodysplastic and/or myeloproliferative neoplasms
and acute myeloid leukemia with myelodysplasia-related changes
predicts concurrent systemic mastocytosis. Mod Pathol. 2020.
https://doi.org/10.1038/s41379-019-0447-x.
9. EscribanoL,Alvarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult
indolent systemic mastocytosis: a long-term study of the Spanish Net-
work onMastocytosis in a series of 145 patients. J Allergy Clin Immunol.
2009;124:514–521.
10. Vaes M, Benghiat FS, Hermine O. Targeted treatment options in mas-
tocytosis. Front Med. 2017;4:110.
